Venös tromboembolism, warfarin och cancer - Ett välkänt samband

Lakartidningen

Volumn 97, Issue 41, 2000, Pages 4554-

  Schulman, Sam ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 24644459026     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Phlegmasia alba dolens. I: Trosseau A. Lectures on clinical medicine, delivered at the Hôtel-Dieu, Paris, France. Cormack JR, trans. London: New Sydenham Society, 1872: 281-95.
2. Baron JA, Gridley G, Weiderpass E, Nyrén O, Linet M, Venous thromboembolism and cancer. Lancet 1998; 351: 1077-80.
3. Sørensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338: 1169-73.
4. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-5.
5. Schulman S, Lindmarker P and the Duration of Anticoagulation Trial. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med 2000; 342: 1953-8.
6. Prandoni P, Lensing AW, Buller HR, Cogo A, Prins MH, Cattelan AM et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992; 327(16): 1128-33.